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Abstract 
Septic complications have been major problems in the management of patients with obstructive jaundice and neonatal jaundice. This 
study investigates effects of unconjugated bilirubin on lymphocyte-mediated cytotoxicity against human tumor target cells. In vitro 
exposure of human peripheral blood lymphocytes (PBL) with bilirubin IX a in bovine albumin solution resulted in a dose-dependent 
decrease of both natural killer activity and antibody dependent cellular cytotoxicity (ADCC) activity. Inhibition of both activities 
correlated with the amounts of intracellular bilirubin. Expression of cell surface CD16, CD56 antigen, and IL-2 receptor /3 chain was 
unchanged in bilirubin-treated PBL as compared to bilirubin-untreated PBL. When bilirubin-treated PBL were cultured with interleukin-2 
(IL-2), a dose-dependent decrease of lymphokine-activated killing activity, ADCC activity, and DNA synthesis was observed. Expression 
of CD56 antigen and IL-2 receptor a chain was unchanged in bilirubin-treated PBL following IL-2 stimulation as compared to bilirubin 
free control. These results suggest that bilirubin inhibits major histocompatibility complex-unrestricted cytotoxicity in both unstimulated 
and IL-2 stimulated lymphocytes. These observations may help explain the increased susceptibility to infection observed in hyperbiliru- 
binemic patients. 
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1. Introduction 
Sepsis is a major complication leading to the high 
mortality in patients with obstructive jaundice and neonatal 
jaundice [1,2]. However, the mechanisms for this increased 
susceptibility to infection are not fully understood. Desmet 
et al. [3] documented that deposition of bilirubin was 
observed in the cytoplasm of infiltrating mononuclear 
leukocytes and Kupffer cells in liver tissue of patients with 
obstructive jaundice. We have previously reported that in 
vitro production of interleukin-1 and interleukin-2 (IL-2) 
has been inhibited in patients with obstructive jaundice, 
and it correlated inversely with serum levels of total 
bilirubin [4]. Scott-Conner et al. [5] reported that mitogen- 
induced proliferation of splenocytes was decreased in a rat 
model of obstructive jaundice, and both serum and cellular 
factors may be involved in this deficit. These results 
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suggest hat bilirubin may be, at least in part, responsible 
for the decreased immune response in hyperbilirubinemia. 
Unconjugated bilirubin is a final product of heme and is 
known to be cytotoxic to various cells [6]. We have 
reported that bilirubin may be incorporated into both 
monocytes and lymphocytes via different energy-depen- 
dent mechanisms [7]. This study was undertaken to investi- 
gate whether or not bilirubin could affect a important 
lymphocyte function, major histocompatibility complex 
(MHC)-unrestricted cytotoxicity. 
2. Materials and methods 
All immunological experiments were performed with 
viability of peripheral blood lymphocytes (PBL) greater 
than 95% as determined by trypan blue dye exclusion. 
2.1. Medium and buffers 
TC-IO medium: RPMI- 1640 medium supplemented with 
10% (v /v )  Bovine Calf Serum supplemented (BCS; Hy- 
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clone Laboratories Inc., Logan, UT), 20 mmol/1 Hepes 
(Sigma Chemical Co., St. Louis, MO), 2 mmol/1 L- 
glutamine (Sigma) and 50 /zg/ml of gentamycin sulfate 
(Sigma). 
BSA-PBS: 3.0 g/d l  bovine serum albumin (BSA; Frac- 
tion V, Sigma) dissolved in 10 mmol/ l  sodium-phosphate, 
pH 7.4, 0.15 mol/ l  NaC1 solution (PBS). 
2.2. Preparation of bilirubin 
10 mg of bilirubin (Sigma) was dissolved in 0.5 ml of 
0.1 N NaOH solution, diluted to 4.0 ml with distilled 
water, and each concentration (from 0 to 24 mg/dl)  was 
prepared by adding BSA-PBS. Bilirubin solution was 
freshly prepared for each experiment. Preliminary studies 
demonstrated that the quantity of NaOH used in the dis- 
solving solution did not affect the cell viability or the 
immunological ssays (data not shown). 
2.3. Preparation of human blood lymphocytes (PBL) 
Mononuclear cells were collected from heparinized 
blood of healthy donors by a centrifugation through lym- 
phocyte separating media (LSM; Organon Teknika Corpo- 
ration, Durham, NC) as described before [7]. Monocytes 
were removed from mononuclear cells by treatment with 
carbonyl iron powder at 37°C for 45 min followed by 
depletion of phagocytic ells using a magnet [8]. The 
remaining cells, designated peripheral blood lymphocytes 
(PBL), consists of a homogenous population of small to 
medium sized lymphocytes. 
2.4. Bilirubin treatment of human peripheral blood lym- 
phocytes 
Bilirubin treatment of freshly-isolated human PBL was 
carried out at 37°C for 60 min at 5 - 106 cells/ml with 0 to 
12 mg/d l  of bilirubin in BSA-PBS as described before [7]. 
2.5. Flow cytometric measurement of intracellular biliru- 
bin 
The amount of intracellular bilirubin was measured 
using a flow cytometry (FACScan; Becton-Dickinson Im- 
munocytometry s stems, Mountainview, CA) as we de- 
scribed before [9]. 
2.6. IL-2 stimulation of bilirubin-treated PBL 
Bilirubin-treated or -untreated PBL (1 to 2.107 cells) 
were incubated at 37°C for 72 h in a humidified atmo- 
sphere of 5% CO 2 at 2.5 • 10  6 cells/ml in TC-10 in the 
presence or absence of 2,000 IU /ml  of recombinant IL-2 
(specific activity 1.8. 10 7 IU /mg;  Cetus Corp., 
Emeryville, CA) in a 15-ml polypropylene tube. This 
concentration of IL-2 induced a maximal level of both 
LAK and ADCC activity (data not shown). After the 
incubation, the cells were washed once with TC-10 medium 
and used for further experiments. The bilirubin treatment 
and the subsequent 72 h incubation with or without IL-2 
did not alter the cell viability as determined by trypan blue 
dye exclusion test. When freshly-isolated PBL were treated 
with bilirubin and further incubated for 72 h in bilirubin- 
free TC-10 medium, a small amount of bilirubin was 
released into the culture medium (less than 0.8 mg/dl). 
This modest level of bilirubin did not affect the IL-2 
stimulation of PBL in both cytotoxic activity and prolifera- 
tive response (data not shown). 
2.7. Chromium release assay 
5~ Cr-release assay was performed as described before 
[10]. K562, human erythroleukemic cell line, and SW1116, 
human colonic carcinoma cell line, with sensitization of a 
rabbit anti-Chang cell (RAC) antibody, were used for 
target cells of NK and ADCC assay of unstimulated PBL, 
respectively. The RAC antibody reacts with most of tumor 
cell lines (data not shown). Bilirubin-treated or -untreated 
PBL were incubated with 5- 10 3 5~Cr-labeled K562 cells, 
or SW1116 cells sensitized with RAC, at 50:1, 25:1, 12:1 
and 6:1 effector cell to target cell (E /T)  ratio. Raji cells, a 
human B lymphocyte cell line, with or without sensitiza- 
tion of the RAC antibody, were used as target cells for 
LAK or ADCC activity of IL-2 stimulated PBL, respec- 
tively. Bilirubin-treated or -untreated PBL after the 72 h 
incubation with or without IL-2 were incubated with 5 • 10  3 
51Cr-labeled Raji cells with or without sensitization of 
RAC at the same E /T  ratio. 
Specific chromium release and lytic unit values at 20% 
lysis of target cells (LU20) were calculated as described by 
Pross et al. [11]. Percent inhibition of NK and ADCC 
activity was calculated on each donor by the following 
equation: (A -B) /A  × 100, where A = LU20 of bilirubin- 
untreated PBL, B = LU20 of bilirubin-treated PBL. 
When bilirubin-treated PBL were incubated with TC-10 
medium in the current assay, a small amount of bilirubin 
was released from cells into the culture supernate (less 
than 0.2 mg/dl). However, this small amount of bilirubin 
released from bilirubin-treated PBL has no effect on the 
chromium-release assay (data not shown). 
2.8. Measurement of DNA synthesis 
2 • 105 cells of bilirubin-treated or -untreated PBL were 
incubated at 37°C for 72 h in a 5% CO 2 incubator in 200 
/xl of TC-10 with or without 2,000 IU /ml  of recombinant 
IL-2 in a well of 96-well fiat bottom microplate. For the 
final 6 h of the incubation 1 /zCi of [3H]thymidine was 
added into each well. The radioreactivity of the cells 
trapped onto the filter paper was estimated by a liquid 
scintillation counter as described before [3]. 
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2.9. Analysis of cell surface antigen by flow cytometry 3. Results 
Prior to the analysis of freshly-isolated PBL with biliru- 
bin treatment, the FACScan was properly adjusted by 
fluorescence compensation so that autofluorescence d - 
rived from intracellular bilirubin which was detected in 
FL2 channel (585 nm), and the fluorescence of FITC 
which was detected at FL1 channel (539 nm), would not 
interfere with each other as described before [9]. All 
antibodies were purchased from Becton-Dickinson except 
control mouse IgG 1 (Sigma) and TU27 (kindly provided by 
Dr. Kazuo Sugamura of Tohoku University, Japan) [12]. 
Expression of IL-2R /3 chain or CD56 antigen on 
freshly-isolated PBL with or without bilirubin treatment 
was studied by an indirect immunofluorescence m thod. 
5 • 10 6 cells were resuspended in 250 /xl of PBS contain- 
ing 20% (v/v) rabbit serum (Sigma) and 0.1 g/dl  of 
NaN 3, and incubated 4°C for 30 rain to block binding of 
cytophilic immunoglobulin to lymphocytes which possess 
Fc y receptor (FcyR). After the blocking, 10 6 cells (50 
/xl) were incubated at 4°C for 30 min with mouse mono- 
clonal antibody, TU27 (anti-human IL-2R /3 chain), anti- 
human Leu-19 (CD56) antibody, or control mouse IgG l 
antibody. The cells were washed 3 times with ice-cold 
PBS containing 2% (v/v) BCS and 1 g/ l  NaN 3 and 
further incubated at 4°C for 30 min with FITC-labeled goat 
anti-mouse immunoglobulin antibody. The cells were 
washed, fixed in 1 ml of PBS containing 10 g/ l  para- 
formaldehyde and analyzed by FACScan. 
Expression of CDI6 antigen on freshly-isolated PBL 
with or without the bilirubin treatment was studied by a 
direct immunofluorescence m thod. After the blocking, 
10 6 cells were incubated at 4°C for 30 min with FITC- 
labeled anti-human Leu-I l a (CD16) antibody or FITC- 
labeled control mouse IgG 1 antibody. The cells were 
washed, fixed, and analyzed by FACScan. 
The bilirubin-treated PBL after the 72 h incubation in 
TC-10 medium resulted in a significant release of intra- 
cellular bilirubin into extracellular medium and only a 
small amount of bilirubin remained inside the cells (less 
than 0.5 • 10-15 mol/cell). No detectable autofluorescence 
were found in these cells, which enables the two color 
analysis for FITC- and phycoerythrin (PE)-labeled antibod- 
ies using FLI and FL2 channels. Bilirubin-treated PBL 
after 72 h incubation with or without IL-2 were incubated 
simultaneously with FITC-labeled anti-Tac IL-2 receptor 
(IL-2R a chain) antibody and PE-labeled anti-human Leu- 
19 (CD56) antibody (control: FITC-mouse IgG 1, and PE- 
mouse IgGz). The cells were analyzed by FACScan. 
Amounts of the antigen were estimated by the mean 
intensity of fluorescence as described before [13,14]. 
2.10. Statistical analysis 
Data were evaluated by the Student's t-test for paired 
samples. 
3.1. NK and ADCC activi~ in bilirubin-treated PBL 
As we reported before, in vitro exposure of human PBL 
to 6 to 12 mg/dl of unconjugated bilirubin in 3.0 g/dl  
BSA solution resulted in a dose-dependent i crease of 
intracellular bilirubin [7]. NK and ADCC activities were 
determined in both bilirubin-treated and -untreated PBL. 
As shown in Table 1, PBL treated with 6 to 12 mg/dl of 
bilirubin showed a dose-dependent decrease of both NK 
and ADCC activity. The inhibition of both activities corre- 
lated well with the amount of intracellular bilirubin (Fig. 
1). 
3.2. Expression of CD16 and CD56 antigen in bilirubin- 
treated PBL 
Both NK and ADCC activities were predominantly 
mediated by NK cells expressing CD16 and CD56 anti- 
gens [15]. CD16 antigen is shown to be a FcTRIIIA, 
through which ADCC is mediated and transduces agonistic 
signals, and triggers cytolytic machinery [16]. CD56 anti- 
gen, isoform of the neural cell adhesion molecules, func- 
tions as an adhesion molecule in a NK cell-target cell 
interaction [17]. The effect of bilirubin treatment on ex- 
pression of these functional molecules was analyzed using 
a flow cytometry. Bilirubin-treated PBL showed no signifi- 
cant difference of CD16 antigen expression from 
bilirubin-untreated PBL in both positivity and amount of 
the antigen (Table 2). Similarly, bilirubin-treated PBL 
showed no significant change of CD56 antigen expression 
(Table 3). 
3.3. LAK, ADCC activity, and proliferative response of 
bilirubin-treated PBL after IL-2 stimulation 
Bilirubin-treated PBL were assayed after 72 h incuba- 
tion with or without IL-2 for LAK and ADCC activity 
(Table 4). IL-2 stimulation augmented cytotoxic activity of 
bilirubin-untreated PBL by approximately 9.6-fold of LAK 
and 3.2-fold of ADCC. Bilirubin-treated PBL showed a 
dose-dependent decrease of both LAK and ADCC activity 
Table 1 
NK and ADCC activity of bilirubin-treated PBL 
Bilirubin NK activity ADCC activity 
dose (mg/dl) (LU20) (LU20) 
0 13.7±9.5 21.1±11.6 
6 8.1±4.0 14.4±8~4 ~ 
8 5.8±3.4* 12.0±10.1 * 
10 4.1±2.2' 8.9±7.4 ** 
12 2.9±1.4" 6.2±6.3** 
Human PBL were treated with bilirubin at 0 to 12 mg/dl, washed and 
assayed for NK and ADCC activity as described in Section 2. Data 
represent the mean_S.D, of 8 healthy donors. * P < 0.05, * * P < 0.01. 
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Fig. 1. Relationship of intracellular bilirubin level and cytotoxic activity 
in bilirubin-treated PBL. Freshly-isolated PBL were treated with bilirubin 
at 0 to 12 mg/dl, washed, and assayed for NK (A) and ADCC activity 
(B) in 8 healthy donors. The quantity of intracellular bilirubin was 
simultaneously determined by a flow cytometry as described in Section 2. 
% inhibition of NK and ADCC activity in bilirubin-treated cells was 
calculated on each donor by comparing the data to bilirubin-untreated 
control cells. 
Table 3 
Expression of CD56 antigen in bilirubin-treated PBL 
Bilirubin % positive amount of antigen 
dose (mg/dl) cells on positive cells 
(arbitrary units) 
0 10.8_+5.8 49.1±6.0 
6 12.5_+6.9 50.7_+7.8 
8 11.8±6.8 50.6±9.1 
10 12.4±6.3 51.3±11.1 
12 12.2±5.2 53.4±10.8 
Human PBL were treated with bilirubin at 0 to 12 mg/dl, washed, and 
expression of CD56 antigen was analyzed by a direct immunofluo- 
rescence method using a flow cytometry as described in Section 2. Data 
represent the mean-+ S.D. of 6 healthy donors. No statistical significance 
was observed between bilirubin-treated and -untreated PBL in either 
positivity or amount of antigen. 
Table 4 
LAK and ADCC activity of bilirubin-treated PBL after IL-2 stimulation 
Bilirubin IL-2 LAK activity ADCC activity 
dose (mg/dl) (LU20) (LU20) 
0 ( - )  2.5_+2.7"** 19.5±13.5"** 
0 (+)  24.1_+12.3 63.3±23.3 
6 (+)  17.9_+12.3' 43.8±14.2 ~** 
8 (+)  12.7±7.3" 35.4_+18.9" 
10 (+)  9.5_+5.9* 26.3_+15.3"** 
12 (+)  6.5_+4.5** 13.4±11.5 ** 
Human PBL were treated with bilirubin at 0 to 12 mg/dl, washed, and 
incubated for 72 h with or without IL-2. The cells were washed and 
assayed for LAK and ADCC activity as described in Section 2. Data 
represent the mean _+ S.D. of 8 healthy donors. Statistical significance was 
determined comparing each data to the bilirubin-untreated PBL with IL-2 
stimulation. * P < 0.05, * * P < 0.01, * * * P < 0.001. 
dent decrease of [3H]thymidine uptake after IL-2 stimula- 
tion. 
after IL-2 stimulation. Subsequently, proliferative response 
against IL-2 was studied in bilirubin-treated PBL (Table 
5). Similarly, bilirubin-treated PBL showed a dose-depen- 
3.4. Expression of lL-2R [3 chain on bilirubin-treated PBL 
Resting lymphocytes response against IL-2 is mediated 
via IL-2R [3 chain [18]. Expression of IL-2R [3 chain on 
Table 2 
Expression of CD16 antigens in bilirubin-treated PBL 
Bilirubin % positive amount of antigen 
dose (mg/dl) cells on positive cells 
(arbitrary units) 
0 11.7±4.2 65.8-+8.2 
6 11.4±4.6 64.5-+7.1 
8 11.6_+3.9 62.8±10.3 
10 11.8_+4.1 60.7_+7.3 
12 12.0_+4.2 63.4_+10.6 
Human PBL were treated with bilirubin at 0 to 12 mg/dl, washed, and 
expression of CD16 antigen was analyzed by a direct immunofluo- 
rescence method using a flow cytometry as described in Section 2. Data 
represent the mean _+ S.D. of 6 healthy donors. No statistical significance 
was observed between bilirubin-treated and -untreated PBL in either 
positivity or amount of antigen. 
Table 5 
DNA synthesis of bilirubin-treated PBL after IL-2 stimulation 
Bilirubin [3H]thymidine uptake (cpm) 
dose (mg/dl) IL-2 ( - ) IL-2 ( + ) 
0 3251 ± 1342 34 579 + 25 432 
6 3042 ± 1485 29 573 + 22153 
8 2874_+ 1205 20537+ 15387 * 
10 2547 + 904 16 769 _+ 11974 * * 
12 1892 _+ 794 * 12 759 -[- 9405 * * 
Human PBL were treated with bilirubin at 0 to 12 mg/dl, washed, and 
incubated for 72 h with or without IL-2. Data represent the mean ___ S.D. 
of 6 healthy donors. Statistical significance was determined comparing 
data of bilirubin to bilirubin-free control in each set. * P < 0.05, * * P < 
0.01. 
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Table 6 
Expression of IL-2R /3 chain in bilirubin-treated PBL 
Bilirubin % positive amount of antigen 
dose (mg/dl) cells on positive cells 
(arbitrary units) 
0 11.5_+5.7 12.5±4.5 
6 12.9±7.7 13.4±6.4 
8 13.1±7.4 13.9±6.7 
10 13.5±6.3 13.8±4.2 
12 13.0±7.7 13.6±5.5 
Human PBL were treated with bilirubin at 0 to 12 mg/dl, washed, and 
expression of IL-2R /3 chain was analyzed by an indirect immunofluo- 
rescence method using a flow cytometry as described in Section 2. Data 
represent the mean _+ S.D. of 6 healthy donors. No statistical significance 
was observed between bilirubin-treated and -untreated PBL in either 
positivity or amount of antigen. 
Table 8 
Expression of IL-2R o~ chain (Tac) on CD56 positive cells after the 
incubation of bilirubin-treated PBL with or without IL-2 
Bilirubin 
dose (mg/dl) 
amount of antigen (arbitrary units) 
IL-2 ( - ) IL-2 ( + ) 
0 32.2 + 19.4 67.0 ± 30.9 
6 27.8 ± 12.4 66.6 _+ 27.2 
8 28.7_+9.7 68.7_+21.5 
10 26.2 ± 10.2 65.0 _+ 25.0 
12 29.3 ± 4.0 65.9 _+ 24.5 
Human PBL were treated with bilirubin at 0 to 12 mg/dl, washed, and 
incubated for 72 h with or without IL-2. Expression of IL-2R a chain 
(Tac antigen) on CD56 positive cells was analyzed by a direct immuno- 
fluorescence method using a flow cytometry as described in Section 2. 
Data represent the mean-+ S.D. of 6 healthy donors. No statistical signifi- 
cance was observed between bilirubin-treated and -untreated PBL in each 
set. 
bi l irubin-treated PBL was investigated in Table 6. Biliru- 
bin-treated PBL showed no significant difference on IL-2R 
/3 chain expression as compared to bi l irubin-untreated 
PBL. 
3.5. Expression of CD56 antigen and IL-2R a chain (Tac) 
in bilirubin-treated PBL after IL-2 activation 
Previous studies suggest that the predominant effector 
cells for both LAK and ADCC activity in IL-2 stimulated 
lymphocytes are CD56 positive NK cells [19,20]. Expres- 
sion of CD56 antigen on bil irubin-treated PBL was studied 
after 72 h incubation with or without IL-2 (Table 7). IL-2 
stimulation significantly augmented amounts of cell sur- 
face CD56 antigen of bi l irubin-untreated PBL. No signifi- 
cantly different, even slightly higher, expression of CD56 
antigen was observed on bil irubin-treated PBL after IL-2 
stimulation as compared to bi l irubin-untreated IL-2 stimu- 
lated PBL. 
IL-2 directly activates CD56 positive NK cells via 
IL-2R /3 chain to induce the activation antigen, IL-2R a 
Table 7 
Expression of CD56 antigen in bilirubin-treated PBL after IL-2 stimula- 
tion 
Bilirubin IL-2 % positive amount of antigen 
dose (mg/dl) cells on positive cells 
(arbitrary units) 
0 ( - )  12.5_+2.3 65.1+19.5 * 
0 (+) 12 .6_+4.0  107.6_+40.2 
6 (+) 13.0_+3.3 118.2_+36.7 
8 (+) 14 .0_+4.6  124.1__+21.0 
10 (+) 14.4_+3.7 130.5_+21.8 
12 (+) 14.65=5.3 125.0+23.5 
Human PBL were treated with bilirubin at 0 to 12 mg/dl, washed, and 
incubated for 72 h with or without IL-2. Expression of CD56 antigen was 
analyzed by a direct immunofluorescence method using a flow cytometry 
as described in Section 2. Data represent the mean_ S.D. of 6 healthy 
donors. Statistical significance was determined comparing each data to 
the bilirubin-untreated PBL with IL-2 stimulation. * P < 0.05. 
chain (Tac antigen) [21]. Expression of IL-2R c~ chain on 
CD56 positive cells was studied in bil irubin-treated PBL 
after the 72 h incubation with or without IL-2 (Table 8). 
Induction of IL-2R ce chain on CD56 positive cells in 
bil irubin-treated PBL after IL-2 stimulation was un- 
changed as compared to bi l irubin-untreated PBL. 
4. Discussion 
The major effector cells of the MHC-unrestricted cyto- 
toxicity (NK, LAK, ADCC) are NK cells [15,19,20]. Fol- 
lowing cell-cell contact with target cells, azurophilic yto- 
plasmic granules are accumulated and reoriented toward 
the target cells. The granules contain cytotoxic mediators, 
such as perforin, granzyme A and B, T IA- I  fragmentins, 
and leukalexin. These mediators may be taken up or 
influxed into the target cells, resulting in the cytolysis. 
Alternative pathway of lymphocyte-mediated cytolysis is a 
programmed cell death triggered via the interaction be- 
tween the Fas antigen and Fas l igand [22]. Approx. 10% of 
NK cells have high density expression of CD56 
(CD56bright). The CD56 bright NK cells constitutively ex- 
press the high affinity heterotrimeric IL-2Ro~/3T, as well 
as the intermediate affinity heterodimeric IL-2R/3y. The 
more abundant CD56 aim NK cells constitutively express 
only the intermediate affinity IL-2R. IL-2 binding to the 
high affinity IL-2R expressed on CD56 bright NK cells 
results in a strong proliferative response, whereas complete 
saturation of the intermediate affinity IL-2R on either 
CD56 bright or CD56 aim NK cells results in enhanced cyto- 
toxic activity with little or no effect of proliferation [23]. 
IL-2R /3 chain is necessary for the transduction of IL-2 
signals in resting NK cells. TU27 monoclonal antibody, 
which specifically reacts with IL-2R /3 chain, abrogated 
both proliferative response and augmentation of cytotoxic 
activity of NK cells to IL-2 [24]. 
In this study, we have demonstrated that bi l irubin in- 
34 Y. Haga et al. / Biochimica et Biophysica Acta 1316 (1996) 29-34 
hibits NK and ADCC activities of unstimulated PBL with- 
out altering the population of CD16 or CD56 positive 
subset, nor the amount of these functional molecules. The 
doses of bilirubin (6 to 12 mg/dl) used in these experi- 
ments can be seen in sera of jaundiced patients. Unconju- 
gated bilirubin is known to be cytotoxic to various cells. 
Previous studies suggest hat bilirubin inhibits various key 
enzymes in cellular functions, such as protein kinase C, 
cAMP-dependent protein kinase and NADPH oxidase 
[25,26]. Kwak et al. [26] reported that the inhibition of 
bilirubin on the NADPH oxidase may be due to the 
binding of the hydrophobic bilirubin compounds to the 
cytosolic components. The inhibition of these enzymatic 
activities may lead to the impaired intracellular events of 
cytolytic machinery. 
Bilirubin also decreases both cytotoxic activity (LAK 
and ADCC) and proliferative response of IL-2 stimulated 
PBL without altering the expression of IL-2R /3 chain. 
Under the current experimental conditions, most intra- 
cellular bilirubin (about 90%) was effluxed into culture 
medium during the 72 h incubation of IL-2 stimulation 
(data not shown). It is unclear whether a prolonged in- 
hibitory effect of bilirubin may persist after intracellular 
bilirubin is effluxed, or whether the residual intracellular 
bilirubin, which may be tightly bound to cellular compo- 
nents, can inhibit IL-2 induced cytolytic activity. Previous 
studies suggest hat IL-2 binds to the IL-2R /3 chain on 
NK cells and initiates a series of events leading to aug- 
mented cytolytic activity and to subsequent synthesis of 
IL-2R c~ chain (Tac antigen) mRNA [21]. The expression 
of IL-2R ce chain on CD56 positive cells in bilirubin- 
treated PBL was unchanged after IL-2 stimulation. These 
results suggest hat the signal transductional pathway to 
induce IL-2R c~ chain may be conserved inbilirubin-treated 
PBL, and that intracellular bilirubin may not inhibit gen- 
eral cellular functions. 
In summary, in vitro exposure of human lymphocytes 
with unconjugated bilirubin results in a significant de- 
crease of MHC-unrestricted cytotoxicity either with or 
without IL-2 stimulation. The altered lymphocyte function 
may contribute to the lethal infectious complications often 
observed in hyperbilirubinemia. 
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